stockportfolio.pro
Neurocrine Biosciences, Inc. P/E Ratio 2009–2025
Neurocrine Biosciences, Inc. (NBIX) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +5.6%/yr over 16 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 30.37 | -26.8% |
| FY 2024 | 41.49 | -22.2% |
| FY 2023 | 53.34 | -30.3% |
| FY 2022 | 76.56 | -17.3% |
| FY 2021 | 92.58 | +301.8% |
| FY 2020 | 23.04 | -91.6% |
| FY 2019 | 275.62 | -15.1% |
| FY 2018 | 324.59 | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | 93.50 | +637.0% |
| FY 2011 | 12.69 | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
Source: Neurocrine Biosciences, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Neurocrine Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeNeurocrine Biosciences, Inc. — frequently asked questions
What is Neurocrine Biosciences, Inc.'s price-to-earnings ratio?
Neurocrine Biosciences, Inc. (NBIX) reported price-to-earnings ratio of 30.37 for fiscal year 2025, per its SEC filings.
How has Neurocrine Biosciences, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, NBIX's price-to-earnings ratio grew at roughly 5.6% per year (compound annual rate), from 12.69 to 30.37.
Where does this data come from?
Figures are computed from Neurocrine Biosciences, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.